Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.77 |
| ▸ | DDB1 | Q16531 | 16/20 | 0.77 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.77 |
| ▸ | TNF | P01375 | 2/20 | 0.77 |
| ▸ | IL1B | P01584 | 2/20 | 0.77 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.77 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.49 |
| ▸ | HTR3B | O95264 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | HTR3A | P46098 | 1/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.49 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.49 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17246852 | 1.00 | CRBN (0.77) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL25834201 | 0.90 | CRBN (0.64) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL19037562 | 0.89 | CRBN (0.61) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL23707575 | 0.89 | DDB1 (0.77) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL26412024 | 0.87 | DDB1 (0.58) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL15930065 | 0.87 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL19250920 | 0.87 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL563317 | 0.87 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL931134 | 0.87 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL369172 | 0.87 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037378-B2 | Variant CD58 domains and uses thereof | NOVARTIS AG (CH) | 2024-07-16 | — | — | US | disclosed |
| US-20240217955-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2024-07-04 | — | — | US | disclosed |
| US-20240025993-A1 | CD19 BINDING MOLECULES AND USES THEREOF | NOVARTIS AG (CH) | 2024-01-25 | — | — | US | disclosed |
| US-20230295322-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOF | NOVARTIS AG (CH) | 2023-09-21 | — | — | US | disclosed |
| US-20230271940-A1 | HETEROARYL SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2023-08-31 | — | — | US | disclosed |
| US-20230255975-A1 | METHODS FOR TREATING CANCER WITH COMBINATION THERAPIES | CELGENE CORPORATION | 2023-08-17 | — | — | US | disclosed |
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230159490-A1 | TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | CELGENE CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230133695-A1 | METHODS AND COMPOSITIONS FOR REJUVENATING CNS GLIAL POPULATIONS BY SUPPRESION OF TRANSCRIPTION FACTORS | UNIVERSITY OF ROCHESTER | 2023-05-04 | — | — | US | disclosed |
| US-20180207185-A1 | METHODS OF TREATING MYELODYSPLASTIC SYNDROMES WITH A COMBINATION THERAPY USING LENALIDOMIDE AND AZACITIDINE | CELGENE CORP (US) | 2018-07-26 | — | — | US | disclosed |
| US-8158653-B2 | Pharmaceutical compositions of 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-amino isoindoline | CELGENE CORPORATION (US) | 2012-04-17 | — | — | US | disclosed |
| US-8034831-B2 | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies | CELGENE CORPORATION (US) | 2011-10-11 | — | — | US | disclosed |
| US-20110172273-A1 | METHODS OF TREATING MYELODYSPLASTIC SYNDROMES USING LENALIDOMIDE | CELGENE CORPORATION | 2011-07-14 | — | — | US | disclosed |
| US-20110104144-A1 | METHODS FOR TREATING CUTANEOUS LUPUS USING AMINOISOINDOLINE COMPOUNDS | CELGENE CORPORATION (US) | 2011-05-05 | — | — | US | disclosed |
| US-20100278779-A1 | METHODS OF TREATING MYELODYSPLASTIC SYNDROMES WITH A COMBINATION THERAPY USING LENALIDOMIDE AND AZACITIDINE | CELGENE CORPORATION | 2010-11-04 | — | — | US | disclosed |
| US-20090155207-A1 | Use of Immunomodulatory Compounds for the Treatment of Transverse Myelitis, Multiple Sclerosis, and Other Disorders | CELGENE CORPORATION | 2009-06-18 | — | — | US | disclosed |
| US-20090088410-A1 | METHODS FOR THE TREATMENT AND MANAGEMENT OF MYELOPROLIFERATIVE DISEASES USING 4-(AMINO)-2-(2,6-DIOXO(3-PIPERIDYL)-ISOINDOLINE-1,3-DIONE IN COMBINATION WITH OTHER THERAPIES | CELGENE CORPORATION | 2009-04-02 | — | — | US | disclosed |
| US-20080317708-A1 | Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3dione | CELGENE CORPORATION | 2008-12-25 | — | — | US | disclosed |
| US-20080206193-A1 | Angiogenesis inhibitors; immunomodulators; side effect reduction | CELGENE CORPORATION | 2008-08-28 | — | — | US | disclosed |
| US-20070066512-A1 | Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels | VERHELLE DOMINIQUE | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037378-B2 | Variant CD58 domains and uses thereof | CD2, CD58, CD2BP2 | CRBN 1199/4885DDB1 511/4885IKZF3 578/4885 |
| US-20090155207-A1 | Use of Immunomodulatory Compounds for the Treatment of Transverse Myelitis, Multiple Sclerosis, and Other Disorders | IL2, MYT1, THPO | CRBN 1748/4885DDB1 816/4885IKZF3 92/4885 |
| US-20080317708-A1 | Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3dione | IL2, IL5, IL15 | CRBN 615/4885DDB1 378/4885IKZF3 33/4885 |
| US-20230133695-A1 | METHODS AND COMPOSITIONS FOR REJUVENATING CNS GLIAL POPULATIONS BY SUPPRESION OF TRANSCRIPTION FACTORS | IKZF3, IKZF1, CXXC4 | CRBN 262/4885DDB1 2196/4885IKZF3 1/4885 |
| US-20090088410-A1 | METHODS FOR THE TREATMENT AND MANAGEMENT OF MYELOPROLIFERATIVE DISEASES USING 4-(AMINO)-2-(2,6-DIOXO(3-PIPERIDYL)-ISOINDOLINE-1,3-DIONE IN COMBINATION WITH OTHER THERAPIES | JAK2, JAK1, MCL1 | CRBN 287/4885DDB1 368/4885IKZF3 103/4885 |
| US-20070066512-A1 | Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels | SERPINA6, TSLP, FCGR3B | CRBN 1547/4885DDB1 2026/4885IKZF3 529/4885 |
| US-20100278779-A1 | METHODS OF TREATING MYELODYSPLASTIC SYNDROMES WITH A COMBINATION THERAPY USING LENALIDOMIDE AND AZACITIDINE | MCL1, AZI2, THPO | CRBN 312/4885DDB1 60/4885IKZF3 327/4885 |
| US-20230295322-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOF | EPCAM, CD40, BCR | CRBN 1323/4885DDB1 286/4885IKZF3 2558/4885 |
| US-20240217955-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | AANAT, HTR2C, AADAT | CRBN 671/4885DDB1 97/4885IKZF3 3119/4885 |
| US-20110104144-A1 | METHODS FOR TREATING CUTANEOUS LUPUS USING AMINOISOINDOLINE COMPOUNDS | SSB, ARG2, ARGLU1 | CRBN 2301/4885DDB1 1201/4885IKZF3 1638/4885 |
| US-20180207185-A1 | METHODS OF TREATING MYELODYSPLASTIC SYNDROMES WITH A COMBINATION THERAPY USING LENALIDOMIDE AND AZACITIDINE | MCL1, AZI2, THPO | CRBN 312/4885DDB1 60/4885IKZF3 327/4885 |
| US-20230271940-A1 | HETEROARYL SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | XDH, SLCO1B3, ROR1 | CRBN 3187/4885DDB1 3477/4885IKZF3 3679/4885 |
| US-20240025993-A1 | CD19 BINDING MOLECULES AND USES THEREOF | CD22, BCL9, CD2 | CRBN 439/4885DDB1 507/4885IKZF3 251/4885 |
| US-20230255975-A1 | METHODS FOR TREATING CANCER WITH COMBINATION THERAPIES | NEK1, NEK11, CDK9 | CRBN 1387/4885DDB1 485/4885IKZF3 266/4885 |
| US-20110172273-A1 | METHODS OF TREATING MYELODYSPLASTIC SYNDROMES USING LENALIDOMIDE | MCL1, THPO, AZI2 | CRBN 243/4885DDB1 85/4885IKZF3 337/4885 |
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | CD4, CRBN, GZMB | CRBN 2/4885DDB1 3336/4885IKZF3 274/4885 |
| US-20080206193-A1 | Angiogenesis inhibitors; immunomodulators; side effect reduction | VEGFA, PGF, TEK | CRBN 1411/4885DDB1 1730/4885IKZF3 447/4885 |
| US-20230159490-A1 | TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | MYD88, CD14, NFATC1 | CRBN 1103/4885DDB1 1956/4885IKZF3 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.